Amoy Diagnostics Co

Amoy Diagnostics Co EBIT

The EBIT of Amoy Diagnostics Co (300685.SZ) as of Nov 5, 2026 is 417.66 M CNY. In the previous year, EBIT was 292.98 M CNY — a change of 42.56% (higher).

EBIT

417.66 MCNY

YoY

42.56%

Last updated:

In 2025, Amoy Diagnostics Co's EBIT was 417.66 M CNY, a 42.56% increase from the 292.98 M CNY EBIT recorded in the previous year.

The Amoy Diagnostics Co EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2021
253.24 M CNY
Jan 1, 2022
287.66 M CNY
Jan 1, 2023
301.25 M CNY
Jan 1, 2024
292.98 M CNY
Jan 1, 2025
417.66 M CNY
Jan 1, 2026 (e)
404.56 M CNY
Jan 1, 2027 (e)
474.67 M CNY
Jan 1, 2028 (e)
542.57 M CNY
The Amoy Diagnostics Co EBIT history
YEAREBITYoY
est542.57 MCNY+14.30%
est474.67 MCNY+17.33%
est404.56 MCNY-3.14%
417.66 MCNY+42.56%
292.98 MCNY-2.74%
301.25 MCNY+4.72%
287.66 MCNY+13.59%
253.24 MCNY+25.28%
202.15 MCNY+24.44%
162.45 MCNY+12.87%
143.92 MCNY+35.33%
106.35 MCNY+70.86%
62.25 MCNY+222.36%
19.31 MCNY+14.23%
16.90 MCNY+1.59%
16.64 MCNY+348.43%
3.71 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amoy Diagnostics Co Revenue

Amoy Diagnostics Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
917.03 M CNY
253.24 M CNY
239.57 M CNY
Jan 1, 2022
842.18 M CNY
287.66 M CNY
263.74 M CNY
Jan 1, 2023
1.04 B CNY
301.25 M CNY
261.48 M CNY
Jan 1, 2024
1.11 B CNY
292.98 M CNY
254.86 M CNY
Jan 1, 2025
1.20 B CNY
417.66 M CNY
357.89 M CNY
Jan 1, 2026 (e)
1.24 B CNY
404.56 M CNY
358.26 M CNY
Jan 1, 2027 (e)
1.39 B CNY
474.67 M CNY
416.01 M CNY
Jan 1, 2028 (e)
1.58 B CNY
542.57 M CNY
475.07 M CNY

Amoy Diagnostics Co Margins

Amoy Diagnostics Co stock margins

The Amoy Diagnostics Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Amoy Diagnostics Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Amoy Diagnostics Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
83.95 %
27.61 %
26.12 %
Jan 1, 2022
81.78 %
34.16 %
31.32 %
Jan 1, 2023
83.05 %
28.87 %
25.06 %
Jan 1, 2024
83.65 %
26.42 %
22.98 %
Jan 1, 2025
82.60 %
34.87 %
29.88 %
Jan 1, 2026 (e)
82.60 %
32.56 %
28.84 %
Jan 1, 2027 (e)
82.60 %
34.21 %
29.99 %
Jan 1, 2028 (e)
82.60 %
34.31 %
30.04 %

Amoy Diagnostics Co Stock analysis

What does Amoy Diagnostics Co do? Amoy Diagnostics Co., Ltd. generates revenue through the sale of tumor precision molecular diagnostic products, including ADx-ARMS, Super-ARMS, NGS, and FISH testing reagents. These reagents are used for detecting non-small cell lung cancer, colorectal cancer, thyroid cancer, and melanoma in tumor tissue specimens and liquid biopsies. The company also offers data software for gene sequencing data analysis and provides testing services via its medical testing institutions for lung cancer, colorectal cancer, and breast cancer. Revenue streams include reagent sales, software licensing, and diagnostic testing services. The primary customers are medical institutions and healthcare providers requiring tumor molecular diagnostics. The ADx-ARMS product line targets tumor tissue specimen detection, while Super-ARMS serves liquid biopsy applications. NGS and FISH products support comprehensive tumor genetic analysis. Testing services focus on lung, colorectal, and breast cancer diagnostics, catering to hospitals and clinics specializing in oncology. The company’s offerings align with the demand for precise cancer diagnosis and treatment planning. Amoy Diagnostics’ revenue model combines product sales with service-based offerings. Reagent products like ADx-ARMS and Super-ARMS are sold to medical facilities for routine tumor testing. Data software for gene sequencing analysis is licensed to research institutions and hospitals. Testing services through its medical testing institutions provide direct diagnostic solutions for specific cancers, enhancing customer retention through integrated service packages. Amoy Diagnostics Co is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Amoy Diagnostics Co's EBIT

Amoy Diagnostics Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Amoy Diagnostics Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Amoy Diagnostics Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Amoy Diagnostics Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Amoy Diagnostics Co stock

EBIT of Amoy Diagnostics Co is 417.66 M CNY in 2025.

EBIT of Amoy Diagnostics Co changed from 292.98 M CNY to 417.66 M CNY, representing a 42.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Amoy Diagnostics Co since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Amoy Diagnostics Co historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Amoy Diagnostics Co

All Key Metrics — Amoy Diagnostics Co